全血AR-V7或AR-V9表达不能预测mCRPC对雄激素轴靶向药物的反应
本研究采用高灵敏度和特异性的全血检测方法,评估37例接受阿比特龙或恩扎卢胺治疗的转移性去势抵抗性前列腺癌(mCRPC)患者基线AR-V7/V9表达与疗效的关系。结果显示AR-V阳性与阴性患者的PSA应答率及PSA无进展生存期均无显著差异,提示基线AR-V表达不能预测治疗结局。
要点
- 全血AR-V7/V9阳性率24%(9/37),与阴性患者PSA应答率无显著差异(66% vs 64%,p=0.9)。
- AR-V阳性与阴性患者中位PSA无进展生存期无显著差异(9.2个月 vs 未达到,p=0.9)。
- 基线AR-V表达不能预测mCRPC患者接受阿比特龙或恩扎卢胺的疗效。
核心结论
- 基线全血AR-V7或AR-V9表达不能预测mCRPC患者接受阿比特龙或恩扎卢胺的治疗反应。
研究设计与样本
- 研究纳入37例开始阿比特龙或恩扎卢胺治疗的mCRPC患者,采用全血检测方法评估基线AR-V7/V9状态。
主要发现
- 24%(9/37)患者为AR-V阳性。
- AR-V阳性与阴性患者PSA应答率分别为66%(6/9)和64%(18/28),差异无统计学意义(p=0.9)。
- AR-V阳性与阴性患者中位PSA无进展生存期分别为9.2个月和未达到,差异无统计学意义(p=0.9)。
临床怎么用
- 对于mCRPC患者,不应仅依据全血AR-V7/V9表达状态决定是否使用阿比特龙或恩扎卢胺。
局限性
- 样本量较小(37例),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. However, these results were not supported by the recently reported ARMOR3-SV phase III clinical trial, which employed an identical circulating tumour cell assay to assess AR-V7 expression. Therefore, the predictive utility of AR-V7 expression in mCRPC remains uncertain, as does any potential association between other AR-Vs and treatment response. To further investigate, we designed a highly sensitive and specific whole blood assay for detecting AR-V7 and AR-V9. We then examined for a correlation between baseline AR-V7/V9 status and treatment outcome in 37 mCRPC patients commencing abiraterone or enzalutamide. Of the patients, 24% (9/37) were AR-V-positive. Notably, prostate-specific antigen (PSA) response rates did not significantly differ between AR-V-positive (6/9) and AR-V-negative (18/28) patients (66% vs 64%, p=0.9). Likewise, median PSA progression-free survival was not significantly different between AR-V-positive and AR-V-negative patients (9.2 mo vs not reached; p=0.9). These data, which support the findings of the pivotal ARMOR3-SV clinical trial, suggest that baseline AR-V expression does not predict outcomes in mCRPC patients receiving abiraterone or enzalutamide. PATIENT SUMMARY: Detection of androgen receptor splice variants (AR-Vs) in circulating tumour cells of advanced prostate cancer patients has been linked to resistance to abiraterone and enzalutamide. We designed a blood test to detect AR-Vs that can be performed more routinely than tests involving circulating tumour cells and found that patients with AR-Vs still benefit from these effective treatments.
引用
- To SQ, Kwan EM, Fettke HC, et al. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018. PMID: 29398263. doi:10.1016/j.eururo.2018.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。